Examining the impact of propranolol on preoperative anxiety and on tumorigenic changes in patients with pancreatic ductal adenocarcinomas: a randomized, triple-blinded, placebo-controlled pilot trial (The IMPULS trial)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506553-37-00

Enrollment

Registered

2023-11-07

Start date

2024-04-23

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic ductal adenocarcinoma (PDAC)

Brief summary

Anxiety levels measured by The Hamilton Anxiety Rating Scale (HAM-A) and by The Hospital Anxiety and Depression Scale (HADS). The European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QoL) for pancreatic cancer will be used to assess quality of life. HRV data calculated from continuous ECG gathered by a Holter monitor. Follow up data: postoperative complications, survival 30-, 90- days and 1, 3-, 5- years after surgery. Blood and tissue sampling

Detailed description

Safety: Changes in resting HR and BP during the intervention. Symptoms and side effects to medicine: light-headedness, lethargy, hypotension, bradycardia and other symptoms/side-effects. Tertiary end points: feasibility and implementation using the APEASE framework

Interventions

DRUGPLACEBO

DRUGPROPRANOLOL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Anxiety levels measured by The Hamilton Anxiety Rating Scale (HAM-A) and by The Hospital Anxiety and Depression Scale (HADS). The European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QoL) for pancreatic cancer will be used to assess quality of life. HRV data calculated from continuous ECG gathered by a Holter monitor. Follow up data: postoperative complications, survival 30-, 90- days and 1, 3-, 5- years after surgery. Blood and tissue sampling	—

Measure

Time frame

—

Secondary

Measure	Time frame
Safety: Changes in resting HR and BP during the intervention. Symptoms and side effects to medicine: light-headedness, lethargy, hypotension, bradycardia and other symptoms/side-effects. Tertiary end points: feasibility and implementation using the APEASE framework	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026